Systemic and renal effects of an ET(A) receptor subtype-specific antagonist in healthy subjects

British Journal of Pharmacology

Volumn 124, Issue 5, 1998, Pages 930-934

  Schmetterer, Leopold ^a,b   Dallinger, Susanne ^a   Bobr, Barbara ^a   Selenko, Nicole ^a   Eichler, Hans Georg ^a   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Endothelin(A) receptors; Endothelins; Glomerular filtration rate; Renal plasma flow; Renal vascular disease

Indexed keywords

4 AMINOHIPPURIC ACID; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; INULIN;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; INULIN CLEARANCE; KIDNEY BLOOD FLOW; KIDNEY PLASMA FLOW; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIN-1; GLOMERULAR FILTRATION RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; PEPTIDES, CYCLIC; PULSE; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; RENAL CIRCULATION; RENAL PLASMA FLOW;

EID: 0031863914     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701923     Document Type: Article

References (20)

1. B receptors limits the efficacy of nonselective endothelin antagonists in vivo. J. Cardiovasc. Pharmacol., 26 (Suppl. 3), S177-S179.
2. ARAI, H., NORI, S., ARAMORI, I., OKHUBU, H. & NAKANISHI, S. (1990). Cloning and expression of a cDNA encoding an endothelial receptor. Nature, 348, 730-732.
3. BERRAZUETA, J.R., BHAGAT, K., VALLANCE, P. & MACALLISTER, R.J. (1997). Dose- and time-dependence of the dilator effects of the endothelin antagonist, BQ-123 in the human forearm. Br. J. Clin. Pharmacol., 44, 569-571.
4. GASIC, S., WAGNER, O.F., VIERHAPPER, H., NOWOTNY, P. & WALDHÄUSL, W. (1992). Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J. Cardiovasc. Pharmacol., 19, 176-180.
5. HAYNES, W.G. (1990). Endothelins as regulators of vascular tone in man. Clin. Sci., 88, 509-517.
6. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 92, 357-363.
7. HAYNES, W.G. & WEBB, D.J. (1994). Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet, 344, 852-854.
8. INOUE, A., YANAGISAWA, M., TAKUWA, Y., MIYAZAKI, H., KIMURA, S. & GOTO, K. (1989). The human endothelial family: three structurally and pharmacology distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A., 86, 2863-2867.
9. KIOWSKI, W., SÜTSCH, G., HUNZIKER, P., MÜLLER, P., KIM, J., OECHSLIN, E., SCHMITT, R., JONES, R. & BERTEL, O. (1995). Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346, 732-736.
10. MOORE, K., WENDON, J., FRAZER, M., KARANI, J., WILLIAMS, R. & BADR, K. (1992). Plasma endothelin immunoreactivity in liver disease and hepatorenal syndrome. N. Engl. J. Med., 327, 1774-1778.
11. RABELINK, A.J., KAASJAGER, H.A.H., BOER, P., STROES, E.G., BRAAM, B. & KOOMANS, H.A. (1994). Effects of endothelin-1 on renal function in humans. Implications for physiology and pathophysiology. Kidney Int., 46, 376-381.
12. RUBANYI, G.M. & POLOKOFF, M.A. (1994). Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev., 46, 325-415.
13. SCHMETTERER, L., FINDL, O., STRENN, K., JILMA, B., GRASELLI, U., EICHLER, H.G. & WOLZT, M. (1997). Effects of endothelin-1 (ET-1) on ocular hemodynamics. Curr. Eye Res., 16, 687-692.
14. SCHNURR, E., LAHME, W. & KÜPPERS, H. (1980). Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin. Nephrol., 13, 26-29.
15. SCHWARTZ SORENSEN, S., MADSEN, J.K. & PEDERSEN, E.B. (1994). Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am. J. Physiol., 266, F411-F418.
16. SOKOLOVSKY, M., AMBAR, I. & GALRON, R. (1992). A novel subtype of endothelin receptors. J. Biol. Chem., 267, 20551-20554.
17. SOPER, C.P.R., LATIF, A.B. & BENDING, M.R. (1996). Amelioration of hepatorenal syndrome with selective endothelin-A antagonist. Lancet, 347, 1842-1843.
18. TOMITA, K., UJIFE, K., NAKANASHI, T., TOMURA, S., MATSUDA, O., ANDO, K., SCHICHIRI, M., HIRATA, Y. & MARUMO, F. (1989). Plasma endothelin levels in patients with acute renal failure. N. Engl. J. Med. 321, 1127.
19. VIERHAPPER, H., WAGNER, O., NOWOTNY, P. & WALDHÄUSL, W. (1990). Effect of endothelin-1 in man. Circulation, 81, 1415-1418.
20. WEBER, C., SCHMITT, R., BIRNBOECK, H., HOPFGARTNER, G., VAN MARLE, S.P., PEETERS, P.A.M., JINKMAN, J.H.G. & JONES, C.R. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther., 60, 124-137.